| Application no. and date | 15715805.6 (espacenet) (Federated) (European Patent Register), 20150402 | | Patent/reg. no. and date | DK/EP 3125885, 20210630 | | Publication date | 20170208 | | Priority no. and date | US 201461975088 P, 20140404, US 201462013573 P, 20140618 | | EP pub. no. and date |
EP 3125885 20170208 | | Effective date | | | Applicant/owner | Astrazeneca AB, 151 85 Södertälje, SE | | Applicant ref. no. | 1509305 | | Inventor | CROSS, Darren Anthony Edward, AstraZeneca R&D Cambridge
Cambridge Science Park
Milton Road
Cambridge
Cambridgeshire CB4 0WG, GB,
EBERLEIN, Catherine Anne, c/o AstraZeneca
Intellectual Property
Alderley Park
Macclesfield
Cheshire SK10 4TG, GB | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | A61K 31/4184 (2006.01) , A61K 31/506 (2006.01) , A61K 31/5377 (2006.01) , A61P 35/00 (2006.01) | | Title | KOMBINATION AF EGFR-INHIBITOR OG MEK-INHIBITOR TIL ANVENDELSE TIL BEHANDLING AF NRAS-MUTERET CANCER | | Int. application no. | GB2015051042 | | Int. publication no. | WO2015150826 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
